Given that, it's hardly encouraging that Biodexa has taken a big step forward ahead of Recursion in the development of its FAP medication. The latter company's investors will be hoping that REC-4881 ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

From sectoral strategies to national plans, public institutions are awash in documents promising transformation: universal health care, green industrialization, and clean cooking for all by 2030. The ...